A Phase I Pharmacokinetic Study to Assess the Cerebrospinal-fluid Exposure of Rilpivirine in HIV-infected Subjects Switching From TDF/FTC/Nevirapine to TDF/FTC/Rilpivirine.

Trial Profile

A Phase I Pharmacokinetic Study to Assess the Cerebrospinal-fluid Exposure of Rilpivirine in HIV-infected Subjects Switching From TDF/FTC/Nevirapine to TDF/FTC/Rilpivirine.

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Jul 2014

At a glance

  • Drugs Rilpivirine (Primary) ; Emtricitabine/tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Pharmacokinetics
  • Most Recent Events

    • 03 May 2014 Status changed to completed, according to ClinicalTrials.gov record.
    • 05 Apr 2013 Accrual to date is 116% according to United Kingdom Clinical Research Network.
    • 08 Feb 2013 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top